Details about the change in management.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Asston Pharmaceuticals announced key management changes effective 30th March 2026 following a board meeting. The company appointed Mr. Sumit Pawar as the new Chief Financial Officer, a Commerce graduate with over 3 years of experience in finance and accounting. Mr. Yashvardhan Tupe, who holds a B.E. in Mechanical Engineering and an M.Sc. in Management and International Business, was appointed as an Additional Non-Executive Director. Additionally, Mr. Sandip Sharma, a qualified Company Secretary with over 2 years of experience in corporate law and governance, was appointed as an Additional Non-Executive Independent Director. The board also approved convening an Extraordinary General Meeting on 28th April 2026, likely to seek shareholder approval for these appointments. None of the new appointees are related to existing directors on the board.
The appointments strengthen the company's leadership with a new CFO and add fresh board expertise, which could improve financial management and governance. For shareholders, these changes suggest active board restructuring, but the EGM in April may seek their approval for formal ratification.